Diabetes
Page 1 • 9 itemsUnlock global diabetes market insights. Get critical pharma intelligence on R&D, regulatory approvals, and investment opportunities for diabetes treatments.
FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Enters Diabetes Market
FDA approves LANGLARA as interchangeable biosimilar to Lantus insulin glargine, marking Lannett Company's entry into diabetes treatment market through Lanexa Biologics.
Novo Nordisk's Oral Ozempic Becomes First FDA-Approved Pill GLP-1 for Type 2 Diabetes with Cardiovascular Protection
Novo Nordisk's oral Ozempic pill receives FDA approval as the first oral GLP-1 medication for type 2 diabetes with cardiovascular risk reduction benefits.
Eli Lilly's Foundayo (Orforglipron) Receives FDA Approval for Obesity Treatment as Company Reports Strong Q1 2026 Results
Eli Lilly announces FDA approval of Foundayo (orforglipron) for obesity treatment alongside positive Phase 3 results and raised full-year guidance in Q1 2026.
Ascletis Completes Enrollment for ASC30 Oral GLP-1 Diabetes Drug Phase II Trial
Ascletis Pharma completes enrollment in Phase II trial of ASC30, an oral GLP-1 receptor agonist for diabetes treatment, with results expected Q3 2026.
Ascletis Completes Enrollment in Phase II Trial of ASC30 Oral GLP-1 Diabetes Drug
Ascletis Pharma completes enrollment of 100 patients in Phase II trial of ASC30, an oral GLP-1 receptor agonist for diabetes treatment, with results expected Q3 2026.
Novo Nordisk's Oral Semaglutide Shows Promise as First GLP-1 Therapy for Children with Type 2 Diabetes
Novo Nordisk's PIONEER TEENS trial demonstrates oral semaglutide significantly reduces blood sugar in children with type 2 diabetes, paving way for regulatory filings.
Lupin Launches Generic Dapagliflozin-Metformin XR Tablets in US as Xigduo XR Alternative
Lupin Limited launches FDA-approved generic dapagliflozin-metformin extended-release tablets in four strengths as bioequivalent alternative to Xigduo XR.
FDA Approves Sanofi's Tzield for Children Age 1+ to Delay Type 1 Diabetes Onset
Sanofi's Tzield becomes first disease-modifying therapy approved for children as young as one year old to delay insulin-dependent Type 1 diabetes progression.
Lilly's Foundayo Shows 57% Mortality Reduction in Landmark ACHIEVE-4 Diabetes Trial
Eli Lilly's Foundayo (orforglipron) demonstrates superior cardiovascular outcomes with 57% lower all-cause death risk vs insulin glargine in Phase 3 trial.